AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05417529
Drug: Standard Preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partecipants receive premedication with midazolam 0,02 mg/kg intravenous. Anesthesia was the same in both groups. Induction was carried out by fentanyl 3mcg/kg, propofol 2 mg/kg and rocuronium at the dose of 1mg/kg to facilitate intubation
Trial: NCT02228512
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
Trial: NCT00007020
Drug: Cholic Acids
RxNorm normalized name: PEPSIN W/BILE SALTS/DEHYDROCHOLIC ACIDS TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-15 mg/kg body weight/day taken orally.
Trial: NCT02516319
Drug: ICG Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02973958
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: See experimental arm description
Trial: NCT02228512
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part B: 750 mg/m2 Day 5
Trial: NCT01415440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosing will parallel that of Lisdexamfetamine.
Trial: NCT02232529
Drug: MIN-101
RxNorm normalized name: OXT-101
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02232529
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00213018
Drug: Carraguard (PC-515)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04083222
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ISIS 757456-matching placebo solution administered as SC injection.
Trial: NCT02240498
Drug: 20% I.V. Fat Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
Trial: NCT00600600
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tigecycline dosage based on age and clinical status of patient.
Trial: NCT01775137
Drug: TBM100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin inhalation powder (TIP) 112mg/b.i.d
Trial: NCT01605305
Drug: FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
Trial: NCT02446652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (orally) starting 1 week before the first day of the QT
Trial: NCT04111341
Drug: PLACEBO
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM Placebo 6g in the morning TCM Placebo 8g in the evening for 12 weeks
Trial: NCT03372954
Drug: BMAC
RxNorm normalized name: Bone Marrow Aspirate Concentrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: retrograde administration on non-selected BMAC via coronary sinus
Trial: NCT00241111
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02345161
Drug: Triple FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
Trial: NCT00598962
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage dependent on clinical factors such as age, weight and patient-specific health status
Trial: NCT04210973
Drug: Anyu Peibo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
Trial: NCT04210973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Capsule, twice per day, oral after breakfast and supper
Trial: NCT04329923
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00887445
Drug: SLV341
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 - 1000mg once daily
Trial: NCT00887445
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04546256
Drug: ADVAIR DISKUS® 500/50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 inhalations of Test and Reference product in each study period
Trial: NCT02046564
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01040130
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of low and high dose and placebo on exercise endurance time in COPD patients
Trial: NCT00990015
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution/suspension to match active drug QD at a single dose.
Trial: NCT00168012
Drug: Immunoglobulins Intravenous (Human)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00562510
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo BID added to stable HAART
Trial: NCT00973908
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
Trial: NCT00973908
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
Trial: NCT00949650
Drug: BIBW 2992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIBW 2992 once daily until progression
Trial: NCT03247998
Drug: General Anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Trial: NCT03247998
Drug: Conscious Sedation with Remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
Trial: NCT02168946
Drug: Best Available Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic(s) chosen by Investigator
Trial: NCT03414918
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hypertensive patients will be exposed to a single oral dose of 150 mg of roxithromycin. A 150-mg oral dose of roxithromycin should yield peak plasma concentrations of 5-12 mcg/mL14, which are higher than the IC50 measured in vitro (0.18-0.53 mcg/mL).
Trial: NCT02457897
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral supplement given every 8 hours
Trial: NCT03401177
Drug: Naproxen 500 Mg
RxNorm normalized name: naproxen 500 MG
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen is used as a tool to dampen the inflammation thought to be present in early phase Tendinopathy
Trial: NCT01852344
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mgs of methylphenidate or a placebo to be administered one hour before task performance
Trial: NCT02307305
Drug: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
Trial: NCT02296840
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 10mg/kg/day every 6-8 hours
Trial: NCT02675517
Drug: Spiolto Respimat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium bromide + Olodaterol
Trial: NCT01832311
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
Trial: NCT00187161
Drug: Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The additional information is contained in the Detailed Description section.
Trial: NCT01963052
Drug: AGS15E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous (IV) infusion
Trial: NCT00743353
Drug: F-18 RGD-K5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
Trial: NCT01046643
Drug: Estradiol (E2)
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
Trial: NCT01030042
Drug: FOLFOX-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
Trial: NCT04110834
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the same procedure as before is used to prepare the nanoemulsion intermediate gel but the active ingredient, itraconazole, is not added then applied twice daily in the same manner
Trial: NCT02893722
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
Trial: NCT02976467
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets are given twice daily over a treatment period of 6 months
Trial: NCT04441931
Drug: LY3832479
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT04441931
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT00379938
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline control
Trial: NCT01161524
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo taken once daily.
Trial: NCT00339079
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
Trial: NCT00339079
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
Trial: NCT04674137
Drug: XC8 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of XC8 100 mg once daily in the morning during 12 weeks of treatment period.
Trial: NCT04674137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet of placebo once daily in the morning during 12 weeks of treatment period.
Trial: NCT02365532
Drug: Placebo to match GS-6615
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to match GS-6615 tablets administered orally
Trial: NCT01618656
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill
Trial: NCT00127218
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo pill daily for 18 months
Trial: NCT00493389
Drug: Adrenocorticotrophic hormone
RxNorm normalized name: Adrenocorticotrophic hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01063205
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
Trial: NCT00299884
Drug: Combination Ezetrol 10 mg and Lipidil Supra 160 mg
RxNorm normalized name: Supra Sulfa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a/a for 6 weeks
Trial: NCT01052012
Drug: SABER-Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injectable Solution; SABER-Placebo/Once
Trial: NCT00502710
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo po daily.
Trial: NCT02805699
Drug: Baofeikang Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
Trial: NCT02805699
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
Trial: NCT03911570
Drug: Glucosamine Sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Therapy with the prescription formulation of crystalline glucosamine sulfate
Trial: NCT03798561
Drug: ASN008 TG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ASN008 TG
Trial: NCT00890968
Drug: Placebo DuraPeel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical gel; once daily (nightly); total duration: 4 weeks
Trial: NCT04799782
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One placebo pill before bed-time
Trial: NCT03596125
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: per os: jelly tablets Intravenous Route: Glucidion G5
Trial: NCT00564629
Drug: Intravenous acetaminophen plus oral placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 gm IV acetaminophen
Trial: NCT00564629
Drug: Oral acetaminophen plus IV placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 1 g PO APAP
Trial: NCT03280550
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received matching placebo as a subcutaneous injection once every 2 weeks or once every 4 weeks. The dose and dosing frequency was determined by serum total IgE level and body weight using the study-drug dosing table.
Trial: NCT02575482
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01466725
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00668525
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, oral administration, once daily dosing for 8 weeks
Trial: NCT03991377
Drug: Treatment as usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once patients are discharged from hospital, they will be treated by the multidisciplinary team of the Specialized Early Intervention Programme for Incipient Psychosis (PAE-TPI) as part of their usual treatment, which consists of a multidisciplinary approach that includes pharmacological treatment and psychological support, from social workers or nursing staff. An individual care plan is drawn up depending on individual needs and may include follow-up psychiatric visits to evaluate clinical status and, if necessary, readjust pharmacological treatment, and psychological visits to assess and detect risk situations and prevent relapses using a non-trauma focused CBT. In no case will psychological treatment focus on PTSD.
Trial: NCT02029430
Drug: 100 mg/m2 aldoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02029430
Drug: 150 mg/m2 aldoxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03259035
Drug: Folfox Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 cycles of q2weekly FOLFOX, or
Trial: NCT03259035
Drug: Capox
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of q3weekly CAPOX
Trial: NCT03787004
Drug: CNTX-6970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose CNTX-6970
Trial: NCT01187212
Drug: Capecitabine/Cisplatin + Sorafenib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
Trial: NCT00882674
Drug: RG1507
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
Trial: NCT02681887
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
Trial: NCT02681887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet identical to circadian
Trial: NCT00911664
Drug: No supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control
Trial: NCT00277472
Drug: Valsartan/Hydrochlorothiazide
RxNorm normalized name: valsartan/hydrochlorothiazide 160 mg-25 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/12.5 mg taken once daily orally
Trial: NCT00004697
Drug: choline chloride
RxNorm normalized name: Choline Chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03806595
Drug: Normal Saline Flush, 0.9% Injectable Solution
RxNorm normalized name: Normal Saline Flush, 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Barre method of intranasal administration will be used to instil 1mL of saline 0.9% in either the nostril ipsilateral to the headache or 1ml in each nostril in cases of bilateral headache.
Trial: NCT00404768
Drug: GSK221149A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg/h and 12 mg/h
Trial: NCT00404768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched Placebo to Drug
Trial: NCT00906256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00717470
Drug: Prograf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00717470
Drug: Advagraf®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02255110
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin will be administered at a dose of 75 mg/m\^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
Trial: NCT00296348
Drug: steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00375934
Drug: diclofenac potassium (XP21L)
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 25 mg capsule, every 6 hours